Sugi Predict

Sugi Predict / Compounds / SCHEMBL15480643

SCHEMBL15480643

SCHEMBL15480643

Cc1nc2cc(S(=O)(=O)N(C)c3ccc(C(=O)NO)cc3)ccc2s1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.61
▸ LMNA P02545 7/20 0.59
▸ SMN1; SMN2 Q16637 6/20 0.59
▸ MAPT P10636 5/20 0.59
▸ KMT2A Q03164 5/20 0.59
▸ MEN1 O00255 4/20 0.59
▸ HPGD P15428 3/20 0.59
▸ KDM4E B2RXH2 3/20 0.59
▸ HTT P42858 3/20 0.59
▸ MAPK1 P28482 2/20 0.52
▸ NOD2 Q9HC29 1/20 0.52
▸ NPC1 O15118 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ POLB P06746 2/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ TRPV1 Q8NER1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15480642 0.88 ALDH1A1 (0.47) ALDH1A1LMNASMN1; SMN2MAPTKMT2A
SCHEMBL15480640 0.86 HDAC6 (0.45) ALDH1A1LMNASMN1; SMN2MAPTKMT2A
SCHEMBL15480626 0.86 CYP1A2 (0.46) ALDH1A1LMNASMN1; SMN2MAPTKMT2A
SCHEMBL23054931 0.82 ALOX5 (0.44) ALDH1A1LMNASMN1; SMN2MAPTKMT2A
SCHEMBL15480586 0.80 ALDH1A1 (0.60) ALDH1A1LMNASMN1; SMN2HTTMAPK1
SCHEMBL19058585 0.78 NPC1 (0.71) ALDH1A1SMN1; SMN2NPC1RAB9ATRPV1
SCHEMBL18407543 0.77 LMNA (0.44) ALDH1A1LMNASMN1; SMN2MAPTKMT2A
SCHEMBL15480625 0.77 GPR55 (0.59) ALDH1A1LMNASMN1; SMN2KMT2AMEN1
SCHEMBL15480620 0.76 MEN1 (0.59) ALDH1A1LMNASMN1; SMN2MAPTKMT2A
SCHEMBL15482223 0.76 SIRT2 (0.44) ALDH1A1LMNASMN1; SMN2MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENT AB (SE) 2017-01-26 — — US disclosed
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB 2014-02-20 — — US disclosed
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB 2014-02-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 ALDH1A1 3068/4885LMNA 489/4885SMN1; SMN2 2901/4885
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 ALDH1A1 3068/4885LMNA 489/4885SMN1; SMN2 2901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.